Studies with 19-Norethisterone CEnanthate in Mammary Carcinoma
By MARY DOUGLAS, M.D., F.F.R., J. A. LORAINE, D.Sc., Ph.D., M.R.C.P.Ed., and J. A. STRONG, M.B., F.R.C.P.Ed. Edinburgh VARIOUS investigators including Epstein et al. (1958) and McGinty and Djerassi (1958) have reported that 19-norethisterone is capable of inhibiting gonadotrophin production in experimental animals. (Estrogenic effects have also been noted after administration of the compound, and it has been suggested (McGinty and Djerassi, 1958 ) that cestrogen production in the body may be responsible for the inhibition of pituitary gonadotrophin secretion. If these claiins are correct, and if norethisterone is indeed capable of inhibiting pituitary function, it is possible that the drug might have some place in the palliative treatment of mammary cancer in humans.
This report concerns the value of 19-norethisterone cenanthate (19NEO) in the management of recurrent and metastatic mammary carcinoma. Studies made on the pharmacological effects of the drug in the same group of patients are also described. A purely clinical study was carried out on a further group of patients in the Radiotherapy Department in Edinburgh, but no further reference will be made to this second group other than to state that the clinical findings confirmed those now reported. Materials and Methods -The present series of patients consisted of 12 women with recurrent or metastatic mammary carcinoma. In addition to clinical and radiological examination the following investigations were also undertaken.
(1) Pituitary gonadotrophin excretion before and during treatment with 19NEO. The assay method used was that of Loraine and Brown (1959). (2) Limited studies on estrogen excretion (Brown et al., 1957) , -total 17-oxosteroid excretion (Vestergaard, 1951) and total 17-hydroxycorticosteroid (170HCS) excretion (Appleby et al., 1955) .
(3) Vaginal smears, taken before and after treatment.
(4) Thyroidfunction, as assessed by estimations of serum protein-bound iodine (PBI) (Zak et al., 1952) before and after treatment, as well as by studies with 1311 (Fraser et al., 1953 It should be pointed out that in one only of the patients described (Case 10) was there evidence of remission of disease, and the effect of treatment on the excretion of gonadotrophins in this patient was similar to that in the other patients in the series.
In the 2 patients studied, the excretion of 17- 3.
-,=duration of treatment.) but during the period covered by these observations neither received any treatment for the disorder of thyroid function. In each instance, the concentration of PBI fell during the period of treatment, and although there are only five pairs of observations, yet the difference between the means was found to be significant (P <0 05).
The results of 1311 excretion tests showed no consistent change attributable to treatment.
In one patient only was there evidence that the progress of the disease might have been accelerated by the treatment, though these findings might conceivably have been coincidental. The results of serum and urine calcium studies in this patient are shown in Fig. 4 . The serum calcium concentration was raised, and the excretion of calcium in the urine was increased after a brief period of treatment with 19NEO. Metabolic balance studies were carried out in 2 patients. Throughout the period of study the patients were on a constant intake consisting basically of Complan, and in the first patient (Fig. 5) it is evident that administration of 19NEO was not accompanied by any consistent change in nitrogen, calcium, sodium, potassium or chloride excretion in the urine. In the second patient (Fig. 6) , who received 560 mg 19NEO weekly, there was evidence of slight retention of nitrogen but the changes were relatively trivial.
Discussion
Although one patient obtained a satisfactory remission of disease while being treated with 19NEO, the drug compares unfavourably with a number of others used in the management of advanced breast cancer, and it is unlikely there- 
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Gonadotrophin excretion was consistently reduced by treatment with 19NEO. Before treatment the amount excreted daily by this group of patients was similar to that found in the majority of women in this age group. It may be noted, however, that in contrast to the findings during treatment with stilbeestrol, gonadotrophin excretion after 19NEO was reduced only to premenopausal levels, rather than abolished completely, or reduced below the level which could be measured by the method in use. Even in Case 12, when the dose of 19NEO used was three times greater than in the other patients, the excretion of gonadotrophins was still not abolished.
In 3 of the patients described estimations of pituitary gonadotrophins in plasma were carried out before and after treatment with 19NEO. In each instance the assays showed a fall in plasma activity after treatment to levels below that at which activity could be detected (Apostolakis, 1959) .
CEstrogen excretion by patients treated with 19NEO increases very considerably (Brown and Blair, 1960 Edinburgh THE pattern of the urinary excretion of cestrogens, pregnanediol and gonadotrophins throughout nine ovulatory menstrual cycles has been described previously (Brown et al., 1958) . The present communication describes the excretion of these substances by two subjects with dysmenorrhoea and one subject with premenstrual tension, before, during and after treatment with norethisterone or its acetate.
The subjects were healthy and were normally active during the periods of investigation. Rectal temperatures were recorded each morning on awakening. Urinary pregnanediol was estimated by the method of Klopper et al. (1955) and urinary gonadotrophins by the method of Loraine and Brown (1959) . Urinary cestrone, oestradiol and cstriol were measured by the methods of Brown (1955) and Brown et al. (1957) . Urinary metabolites of norethisterone and its esters interfere in these methods causing the cestradiol values by both methods and the cestrone values by the latter method to be high; they do not, however, interfere with the determination of cestriol (Brown and Blair, 1960) .
The first subject, who had regular menstrual cycles with severe menstrual and premenstrual dysmenorrheea, was studied throughout four menstrual cycles. The results are shown in Fig. 1 . During the first cycle in which she did not receive any treatment the levels of aestrogen, pregnanediol and gonadotrophin excretion were within the normal range but there was no rise in gonadotrophin excretion at mid-cycle. The temperature chart was biphasic and there was a gain in weight premenstrually. There was severe dysmenorrhoea for three days premenstrually and menstruation lasted five days.
During the second cycle norethisterone acetate (6 mg per day) was administered orally from the fifth to the twenty-fifth day. The gonadotrophin excretion was similar to that during the first cycle. There was no rise in pregnanediol or aestrogen excretion during the second half of the cycle, although a peak of oestrogen excretion occurred at approximately mid-cycle. The temperature chart remained biphasic and there was a gain in weight premenstrually. There was severe dysmenorrhoea for three days before menstruation and the latter lasted four days. The findings in this cycle are compatible with the view that luteal function but not follicular function was depressed by the administration of norethisterone acetate.
During the third cycle norethisterone acetate (12 mg per day) was administered orally from the fifth to the twenty-fifth day. CEstrogen and pregnanediol excretion remained fairly constant throughout the cycle. Gonadotrophins were excreted throughout the cycle with possibly a
